Skip to main content
GPCR
NASDAQ Life Sciences

Structure Therapeutics Secures $100M Upfront Payment in GLP-1 Patent Licensing Deal with Genentech/Roche

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$62.77
Mkt Cap
$4.133B
52W Low
$13.22
52W High
$94.9
52W Position info
375% above low
Off High info
34% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

GPCR has more than doubled off its 52-week low of $13.22.

Summary

Structure Therapeutics' subsidiary secured a non-exclusive patent licensing agreement with Genentech and Roche, receiving a $100 million upfront payment and future royalties for a GLP-1 receptor agonist compound.


Key Events · M&A and Partnerships · GPCR

  • Material Licensing Agreement

    Gasherbrum Bio, a wholly-owned subsidiary of Structure Therapeutics, entered into a non-exclusive, royalty-bearing license agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (GNE).

  • Significant Upfront Payment

    Genentech will pay Gasherbrum a one-time, non-refundable payment of $100 million within 30 days of the agreement's execution.

  • Future Royalty Potential

    Genentech also agreed to pay Gasherbrum royalties at a low single-digit rate on net sales of GNE Products containing CT-996, a proprietary GNE compound.

  • Preserves Core Programs

    The license covers patents for a class of oral GLP-1 receptor agonists different from aleniglipron and does not encumber Structure Therapeutics' ongoing development programs.


Analysis · GPCR · Life Sciences

Structure Therapeutics' subsidiary, Gasherbrum Bio, has entered into a significant licensing agreement with Genentech and F. Hoffmann-La Roche. This deal provides a substantial $100 million non-refundable upfront payment and potential future royalties, significantly bolstering the company's financial position. Crucially, the non-exclusive license covers a class of GLP-1 receptor agonists distinct from Structure Therapeutics' ongoing core programs, allowing them to monetize intellectual property without encumbering their primary pipeline assets. This transaction provides non-dilutive capital and validates a portion of their patent portfolio, enhancing their ability to fund future development.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GPCR was trading at $62.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $13.22 to $94.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GPCR - Latest Insights

GPCR
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $20.95
Real-time Price: $18.17 info
Change: -$2.78 (-13%) info
Market Cap: $1.325B info
GPCR
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $18.17 info
Change: -$3.24 (-15%) info
Market Cap: $1.325B info
GPCR
Nov 09, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.41
Real-time Price: $18.17 info
Change: -$3.24 (-15%) info
Market Cap: $1.325B info
GPCR
Sep 22, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $36.78
Real-time Price: $18.17 info
Change: -$18.61 (-51%) info
Market Cap: $1.325B info
GPCR
Sep 08, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.60
Real-time Price: $18.17 info
Change: -$29.43 (-62%) info
Market Cap: $1.325B info